G12A gene which is the human homolog of the Kirsten rat sarcoma-2 virus oncogene.
Kirsten-Ras (KRAS)
A membrane associated guanosine triphosphatase.
A proto-oncogene- located on chromosome 12, and encodes intracellular membrane bound RAS protein.
KRAS mutations are drivers of tumorigenesis and influence the prognosis and treatment response, with outcomes varying according to the specific biologic variant involved.
The RAS guanisine triphosphate complex activates signaling pathways such as RAF/MEK/ERK & PI3K/AKT/mammalian targeted rapamycin, which play key roles in cell proliferation, differentiation, and survival.
KRAS proteins function as molecular switches,, toggling between an active and inactive state, depending on whether they bind to guanosine phosphate, GDP or GTP: this transition between states is critical for controlling downstream, signaling pathways involved in cellular processes.
KRAS activation typically begins with the engagement of in membrane, tyrosine kinase receptors, such as fibroblasts growth factor receptors, epidermal growth, factor (EGFR) receptor, human epidermal growth factor receptor 2(HER2) and human epidermal growth factor receptor three (HER3).
In its active state, KRAS proteins, dimmerize and initiate downstream signaling cascades that regularly key, cellular processes, such as growth, differentiation, and survival.
Mutant KRAS signals preferentially through the RAF-MEK-ERK pathway with ERK having effects of multiple cellular processes.
The most frequently mutated oncogene in human cancers.
KRAS accounts for 85% of RAS mutations observed in human cancers.
KRAS activating mutations, particularly in codon 12, 13, and 61 lead to constitutive activation of the protein by switching KRAS-GDP to KRAS-GTP, bypassing normal regulatory mechanisms and maintaining downstream signaling independently of extra cellular growth signals.
This persistent activation, promotes uncontrolled cell proliferation, survival, and metastasis.
KRAS mutations are particularly common in gastrointestinal malignancies, occurring up to up to 40 to 50% of cases of colorectal cancer and 90% of cancers of pancreatic ductal adenocarcinoma.
KRAS mutations are mostly missense mutations leading to permanent and constitute of activation of the RAS oncoprotein, promoting tumorigenesis.
KRAS protein is a GTPase that integrates activity from upstream receptor tyrosine kinase and signals downstream to regulate cell growth.
Oncogenic mutations in KRAS shift the balance toward perpetual activity and unchecked cellular growth.
The most common codon 12 mutation sub type is G12C.
KRAS mutations occur in approximately 25% of non-small cell lung cancers, approximately 40% of adenocarcinomas and 0.5 to 4% of squamous lung cancers.
KRAS mutated non-small cell lung cancers are generally associated with smoking, current or former, increased program death ligand-1 expression on tumors, increased tumor mutational burden, and increased tumor infiltrating lymphocyte count.
KRAS driven NSCLC is frequently associated with a history of smoking, high tumor, mutational burden, and genomics signatures of tobacco smoke exposure.
KRAS mutations are seen in up to 90% of patients with pancreatic ductal adenocarcinoma.
The KRAS G12C mutation occurs in codon 12 and results in the substitution of a glycine with cysteine.
KRASG 12 C inhibitors covalently binds to the unique cysteine codon 12 of the KRASG 12 C mutant effectively locking it in an inactive GTB-bound state and blocking the apparent signaling that drives cancer progression.
The KRAS G12C mutation is induced by smoking and is responsible for about 12% of lung adenocarcinomas.
The KRAS G12C proteins keeps KRAS in the active bound state and drives oncogenenic signaling through multiple down stream pathways: They promote tumor cells, survival, proliferation, and metastasis.
KRAS G12C mutation occurs in approximately 3 to 4% of patients with metastatic colorectal cancer.
In a phase 3 trial of KRAS G12 C inhibitor Sotorasib plus Panitumumab an EGFR inhibitor in patients with refractory colorectal metastatic cancer improved survival vs standard treatment.
KRASG 12 C retains some GTPase activity which enable selective inhibition by covalent inhibitors that bind to the cysteine residue unique to this mutation.
Mutations like KRAS g12C and KRAS G 12 V significantly reduce GTPase activity so they are more challenging to target with similar approaches.
Encodes a GTP-binding protein that functions as a self-activating signal transducer by cycling GDP to GTP bound states.
Encodes guanosine triphosphatase bound states to regulate signal transduction.
KRAS medications are often associated with resistance to target therapies and poor outcomes in patients with cancer.
KRAS can be activated by extracellular stimuli and initiate downstream signaling pathways responsible for fundamental cell processes.
Stimulated by the epidermal growth factor receptor (EGFR) and other cell surface receptors.
The KRAS gene is essential for cell division because it sends signals to a biological on/off switch that tells cells went to start and stop dividing.
When mutated it creates a misshapen protein that prevents the switch from turning off and the cells never stop the dividing, forming a tumor.
Mutant KRAS cells have decreased major histocompatibility class 1 expression, upregulation of programmed cell death-ligand 1, and promotion of immuno suppressive immune cell populations in the tumor microenvironment.
Mutant KRAS cells enhance recruitment, accumulation, and maintenance of myeloid derived suppressor cells to the tumor microenvironment.
The above changes suggest that these alterations occur early in the carcinogenesis process and promote cancer cell survival, invasion, and migration.
Downstream effect to pathways of oncogenicgenic KRAS include mitogenic protein kinase (MAPK) come phosphatidylinoitol 3 kinase (PI3K, and RAS-like GEF, all the factors are responsible for cell proliferation, cell cycle regulation, metabolic changes, cell survival, and cell differentiation.
KRAS dysregulation lead to tumor growth by controlling interactions between cancer cells and the micro environment, affecting therapeutic response.
KRAS mutations are prevalent in common malignancies, such as lung and colorectal cancer.
The three Human Cancer types with the highest rate of KRAS mutations are: pancreatic (88%), colorectal (45–50%), and lung cancer (31–35%).
KRAS mutations are heterogeneously distributed across GI cancers with high rates in pancreatic duct cancer, colorectal cancer, biliary cancer.
In pancreatic duct cancer, the most prevalent variants or GD 12 D, G 12 V, and G 12 R.
In colorectal cancer KRAS mutations are also common with G12D, G No12V, an G13D the most frequent.
BilIARY cancer is including cholangiocarcinoma exhibit KRAS mutations in approximately 15 to 20% of cases, with G 12 D the most common.
KRASG 12 C mutations are rare in G.I. cancer occurring in approximately 1.5% of pancreatic duct cancer, 3.6% in colorectal cancer in one percent in biliary tract cancers.
KRAS G12 mutation is associated with poor prognosis compared to other KRAS mutations as well as KRAS wild type tumors.
The glycine-to-cysteine mutation at position 12 favors the active form of the KRAS protein, resulting in a predominantly GTP-bound KRAS onco-proteins and enhanced proliferation and survival in tumor cells.
The most common variants of the KRAS 12 codon mutation include V, D, and C.
KRAS G12C mutation is noted in lung cancer and colon rectal cancers and less frequently endometrial, pancreatic, and ovarian cancers.
As many as 5% of patients with colorectal cancer have the KRAS G12C mutation.
KRAS mutations occur in nearly 40% of patients with lung cancer, and among patients with colorectal cancer, as many as 5% have a KRAS G12C mutation.
G12C mutation is more common in women.
In colorectal cancer KRAS G12 mutations are associated with a poor prognosis than other G 12 mutations, whereas KRAS G12 R has a more favorable prognosis.
KRAS mutations are associated with resistance to anti EGFR therapies limiting affecting this of targeted treatments for patients with KRAS mutations.
Overall KRAS mutations are frequently linked to aggressive disease and poor outcome in G.I. cancers,
KRAS mutations are observed in up to 30% of patients with NSCLC and occur primarily at codons 12 and 13.
KRAS gene-small G protein downstream of EGFR can acquire mutations in exon 2 and can isolate the EGFR pathway and make EGFR inhibitor ineffective.
Ras gene family consists of H-Ras, N-Ras and K-Ras.
The Ras proteins are usually small triphosphate binding proteinsof several signaling pathways that play key roles in signal transduction resulting in cellular proliferation and transformation.
Right-sided colorectal cancers have a high likelihood to have a KRAS mutation.
Mutations associated with poor response to epithelial growth factor inhibitor treatment in colorectal cancer.
KRAS mutations are prevalent in solid tumor cancerous, and about 40-50% of colon cancer have a mutation in RAS pathway which includes the KRAS, NRAS, and BRAF genes.
RAS pathway mutations solid tumors less likely to respond to current therapies.
Patients with KRAS mutations in exon 2 do not have a response to anti-EGFR therapy and they have inferior outcomes if this therapy is combined with oxaliplatin containing chemotherapy regimens.
Absence of gene mutations associated with favorable outcomes with the use of epithelial growth factor inhibitors cetuximab (Erbitux) and panitumumab (Vectibix).
Patients with metastatic colon cancer with KRAS codon 12-or 13-mutated tumors are presently excluded from treatment with anti-epidermal growth factor receptor monoclonal antibody treatments.
KRAS mutations are usually mutually exclusive with other talkable congenic drivers such as EGF or or ALK mutations.
KRAS G12 C is the most common variant accounting for nearly 40% of all KRAS mutations – 12 NSCLC‘s.
It is the KRAS mutation status that is the most important predictor for the lack of benefit from anti-EGFR therapy.
In a study of 89 patients with colon cancer treated with cetuximab, after failure of irinotecan based regimens, KRAS mutations at codon 12/13 were identified in 27% of patients with a treatment response of 0%, while treatment response was 40% in patients without KRAS mutations, the median progression free survival was 10 weeks versus 31.4 weeks and overall survival 10.1 months versus 14.3 months, respectively (Lievre).
CO 17 study a randomized trial showed that among colorectal cancer patients that failed chemotherapy, monotherapy with cetuximab improved overall survival and progression free survival than did supportive care.
The addition of cetuximab to FOLFIRI chemotherapy as first-line therapy in metastatic colon cancer improves survival in patients with KRAS wild type disease (Van Cutsem et al).
The addition of cetuximab in patients with KRAS wild type disease to chemotherapy resulted in significant improvements in overall survival with the median survival 23.5 versus 20 months, progression free survival median 9.9 versus 8.4 months and response rates of 57.3% versus 39.7% compared with FOLFIRI alone, confirming KRAS as a powerful biomarker predictor for cetuximab efficacy. (Van Cutsem E et al).
Benefits in patients treated with panitumumab limited to wild type KRAS tumors.
KRAS mutations are variable in their biologic characteristics and our tumor type specific.
KRAS in colorectal tumors have both codon 12 and codon 13 mutations 79% and 17.6%, respectively.
In cetuximab treated patients the presence of a glycine (G) to aspartic acid (D) change at codon 13 of KRAS and is associated with the intermediate survival, between that of patients with KRAS wild type tumors and tumors harboring a KRAS mutation at glycine-12.
A retrospective review examining the effects of KRAS mutations on tumor response in unresectable colorectal liver metastases revealed worse overall outcomes and lower rates of conversion to resection with combination hepatic arterial infusion (HAI) pump therapy and systemic chemotherapy when compared against wild-type KRAS.
KRAS-wild type patients have a more pronounced response to HAI therapy compared with patients with KRAS mutations.
Smoking a strong associated with KRAS mutations in lung cancer.
KRAS mutations in more common in adenocarcinoma of the lung (20–40%) and less common, about 5%, in squamous non-small cell lung cancer.
KRAS is more common in cigarette smokers versus non-smokers (30% versus 11%) and in Western versus Asian populations (26% versus 11%).
The presence of a KRAS gene mutation in colorectal cancer is associated with worse prognosis for liver metastases as well as shorter survival following resection.
KRAS mutated pancreatic cancers which are 75-95% of the lesions, are almost invariably codon 12 mutations.
In small cell lung cancer more than 90% of KRAS mutations are located in codon 12.
KRAS mutant NSCLC are often linked to smoking, and is frequently associated with high mutational burden.
Studies show that immunotherapy combined with chemotherapy significantly prolong the overall and progression free survival in patients with KRAS mutant NSCLC compared with chemotherapy alone.
Agents that show efficacy in treating KRAS G12 C mutated cancers include sotorasib, adagrasib and divarasib.
KRAS G12D is a mutation in the KRAS gene, which is most commonly mutated oncogene in cancer.
KRAS is a protein that acts as an on-off switch that controls cell growth, maturation, and death.
When the KRAS protein receives signals, it activates and tells the cell to grow and divide.
However, some mutant forms of KRAS, like KRAS G12D, remain active even when there are no growth signals, causing uncontrolled cell growth and cancer.
These mutations can also create a more immunosuppressive tumor microenvironment and make tumors more resistant to immunotherapy than other KRAS mutations.